Aytu BioPharma, Inc. (AYTU) 10-Year Financial Performance & Capital Metrics

AYTU • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

AboutAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.Show more

Revenue $66M +1.8%
EBITDA -$2M -147.7%
Net Income -$14M +14.4%
EPS (Diluted) -2.16 +24.5%
Gross Margin 69.04% -8.3%
EBITDA Margin -3.69% -146.9%
Operating Margin -11.79% -383.1%
Net Margin -20.43% +15.9%
ROE -58.1% -23.0%
ROIC -33.47% -894.7%
Debt/Equity 1.21 +104.2%
Interest Coverage -2.11 -536.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)
✓Strong 5Y sales CAGR of 19.2%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 13.4% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y73.94%

5Y19.16%

3Y-11.78%

TTM-5.39%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-109.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM-147.99%

ROCE

10Y Avg-70.95%

5Y Avg-35.52%

3Y Avg-13.29%

Latest-13.3%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.49B	135.33	41.13	24.81%	15.95%	14.25%	4.13%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.97B	51.80	39.24	8.94%	-2.8%	-1.82%	5.76%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.94M	7.01	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.02M	2.75	-1.27	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	429.45M	3.52	-6.90	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.50	-42.16	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	17.39B	35.17	-4042.53			-67.02%		0.01

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	2.56M	3.22M	3.66M	7.32M	27.63M	65.63M	96.67M	107.4M	65.18M	66.38M
Revenue Growth %	8.79%	0.26%	0.14%	1%	2.77%	1.38%	0.47%	0.11%	-0.39%	0.02%
Cost of Goods Sold+	957.08K	1.42M	2.05M	2.2M	8.28M	36.43M	46.39M	40.77M	16.13M	20.55M
COGS % of Revenue	0.37%	0.44%	0.56%	0.3%	0.3%	0.56%	0.48%	0.38%	0.25%	0.31%
Gross Profit+	1.61M	1.8M	1.61M	5.12M	19.35M	29.2M	50.28M	66.63M	49.05M	45.83M
Gross Margin %	0.63%	0.56%	0.44%	0.7%	0.7%	0.44%	0.52%	0.62%	0.75%	0.69%
Gross Profit Growth %	8.24%	0.12%	-0.11%	2.18%	2.78%	0.51%	0.72%	0.33%	-0.26%	-0.07%
Operating Expenses+	15.81M	20.66M	19.45M	21.96M	40.48M	88.07M	160.19M	83.7M	50.65M	53.66M
OpEx % of Revenue	6.17%	6.41%	5.32%	3%	1.47%	1.34%	1.66%	0.78%	0.78%	0.81%
Selling, General & Admin	8.83M	17.61M	17.73M	19.24M	31.06M	55.81M	69.88M	70.08M	42.04M	38.28M
SG&A % of Revenue	3.44%	5.47%	4.84%	2.63%	1.12%	0.85%	0.72%	0.65%	0.64%	0.58%
Research & Development	6.32M	1.35M	167.59K	589.07K	1.72M	5.62M	12.66M	4.09M	2.77M	1.33M
R&D % of Revenue	2.47%	0.42%	0.05%	0.08%	0.06%	0.09%	0.13%	0.04%	0.04%	0.02%
Other Operating Expenses	664.71K	1.71M	6.28M	2.14M	7.7M	26.64M	77.65M	9.52M	5.84M	14.05M
Operating Income+	-21.7M	-20.13M	-19.7M	-16.85M	-21.13M	-58.87M	-109.91M	-17.07M	-1.59M	-7.83M
Operating Margin %	-8.47%	-6.25%	-5.38%	-2.3%	-0.76%	-0.9%	-1.14%	-0.16%	-0.02%	-0.12%
Operating Income Growth %	-1.84%	0.07%	0.02%	0.14%	-0.25%	-1.79%	-0.87%	0.84%	0.91%	-3.92%
EBITDA+	-20.83M	-18.28M	-17.85M	-14.61M	-15.42M	-49.67M	-99.76M	-8.25M	5.13M	-2.45M
EBITDA Margin %	-8.13%	-5.67%	-4.88%	-2%	-0.56%	-0.76%	-1.03%	-0.08%	0.08%	-0.04%
EBITDA Growth %	-1.77%	0.12%	0.02%	0.18%	-0.06%	-2.22%	-1.01%	0.92%	1.62%	-1.48%
D&A (Non-Cash Add-back)	874.79K	1.84M	1.85M	2.24M	5.71M	9.2M	10.15M	8.81M	6.72M	5.38M
EBIT	-22.69M	-19.97M	-17.84M	-16.85M	-17.92M	-38.24M	-38.1M	-12.09M	-5.32M	-10.04M
Net Interest Income+	-5.49M	-2.53M	-749.42K	0	0	0	-147.48M	-4.96M	-4.79M	-3.7M
Interest Income	0	0	0	0	0	0	14K	0	0	0
Interest Expense	5.49M	2.53M	749.42K	0	0	0	147.5M	4.96M	4.79M	3.7M
Other Income/Expense	-6.48M	-2.38M	9.51M	-10.29M	7.51M	840K	1.02M	14K	-8.79M	-5.92M
Pretax Income+	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.03M	-108.89M	-17.05M	-10.38M	-13.74M
Pretax Margin %	-11%	-6.99%	-2.78%	-3.71%	-0.49%	-0.88%	-1.13%	-0.16%	-0.16%	-0.21%
Income Tax+	0	0	0	20.04M	0	259K	-110K	0	2.14M	437K
Effective Tax Rate %	1%	1%	1%	1.74%	1%	1%	1%	1%	1.53%	0.99%
Net Income+	-28.18M	-22.51M	-10.19M	-47.17M	-13.62M	-58.29M	-108.78M	-17.05M	-15.84M	-13.56M
Net Margin %	-11%	-6.99%	-2.78%	-6.44%	-0.49%	-0.89%	-1.13%	-0.16%	-0.24%	-0.2%
Net Income Growth %	-2.65%	0.2%	0.55%	-3.63%	0.71%	-3.28%	-0.87%	0.84%	0.07%	0.14%
Net Income (Continuing)	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.29M	-108.78M	-17.05M	-12.52M	-14.18M
Discontinued Operations	0	0	0	0	0	0	0	0	-3.32M	620K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-193194.38	-3061.23	-1210.28	-60.20	-69.60	-74.01	-5.11	-2.86	-2.16
EPS Growth %	-1.35%	0.85%	0.98%	0.6%	0.95%	-0.16%	-0.06%	0.93%	0.44%	0.24%
EPS (Basic)	-999999.00	-193194.38	-3061.23	-1210.28	-60.20	-69.60	-74.01	-5.11	-2.86	-2.16
Diluted Shares Outstanding	22	117	3.33K	38.97K	230K	840K	1.47M	3.34M	5.54M	6.28M
Basic Shares Outstanding	22	117	3.33K	38.97K	230K	840K	1.47M	3.34M	5.54M	6.28M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	10.12M	3.03M	9.47M	15.43M	75.42M	105.23M	59.93M	72.83M	61.89M	79.18M
Cash & Short-Term Investments	9.1M	802.33K	7.01M	11.04M	48.08M	49.65M	19.36M	22.98M	20.01M	30.95M
Cash Only	8.05M	802.33K	7.01M	11.04M	48.08M	49.65M	19.36M	22.98M	20.01M	30.95M
Short-Term Investments	1.04M	0	0	0	0	0	0	0	0	0
Accounts Receivable	162.43K	528.04K	578.78K	1.74M	5.63M	28.18M	21.71M	28.94M	23.53M	31.16M
Days Sales Outstanding	23.14	59.83	57.72	86.8	74.41	156.7	81.98	98.34	131.74	171.31
Inventory	524.71K	1.31M	1.34M	1.44M	10M	16.34M	10.85M	11.99M	12.14M	11.43M
Days Inventory Outstanding	200.11	337.93	238.34	238.7	440.72	163.69	85.37	107.4	274.75	203.08
Other Current Assets	121.98K	75.21K	100K	250K	5.99M	1.29M	633K	868K	1.12M	0
Total Non-Current Assets+	14.22M	11.97M	11.59M	19.29M	77.87M	160.43M	77.69M	65.01M	56.97M	45M
Property, Plant & Equipment	231.43K	647.25K	219K	203.73K	893K	8.7M	6.3M	3.87M	1.52M	1.59M
Fixed Asset Turnover	11.07x	4.98x	16.71x	35.93x	30.94x	7.54x	15.35x	27.76x	42.83x	41.67x
Goodwill	221K	238.43K	0	0	28.09M	65.8M	0	0	0	0
Intangible Assets	13.55M	11.08M	11.37M	19.08M	48.85M	85.46M	70.63M	58.97M	52.45M	42.2M
Long-Term Investments	0	0	0	0	0	-10.91M	0	0	0	0
Other Non-Current Assets	216.36K	2.89K	4.72K	2.2K	33K	465K	766K	792K	2.23M	1.2M
Total Assets+	24.34M	15M	21.06M	34.72M	153.29M	265.67M	137.62M	137.84M	118.86M	124.18M
Asset Turnover	0.11x	0.21x	0.17x	0.21x	0.18x	0.25x	0.70x	0.78x	0.55x	0.53x
Asset Growth %	0.34%	-0.38%	0.4%	0.65%	3.41%	0.73%	-0.48%	0%	-0.14%	0.04%
Total Current Liabilities+	10.1M	3.61M	3.39M	5.37M	28.76M	109.44M	64.44M	69.02M	62.23M	63.06M
Accounts Payable	2.32M	2.22M	2.12M	2.13M	11.64M	19.25M	10.99M	13.48M	10.31M	10.6M
Days Payables Outstanding	885.77	571.8	377.3	353.64	513.05	192.91	86.45	120.67	233.41	188.28
Short-Term Debt	0	0	0	0	982K	24.6M	3.81M	8.74M	4.96M	10.92M
Deferred Revenue (Current)	0	0	0	0	339.34K	1000K	0	0	0	0
Other Current Liabilities	6.58M	1.05M	734.43K	2.23M	8M	1.47M	23.84M	41.12M	42.35M	26.14M
Current Ratio	1.00x	0.84x	2.79x	2.87x	2.62x	0.96x	0.93x	1.06x	0.99x	1.26x
Quick Ratio	0.95x	0.48x	2.40x	2.60x	2.27x	0.81x	0.76x	0.88x	0.80x	1.07x
Cash Conversion Cycle	-662.53	-174.05	-81.25	-28.15	2.08	127.48	80.89	85.07	173.08	186.1
Total Non-Current Liabilities+	4.15M	7.39M	4.24M	22.26M	29.52M	18.66M	28.87M	29.47M	28.91M	42.15M
Long-Term Debt	0	0	0	0	0	2.8M	14.2M	20.86M	10.88M	10.89M
Capital Lease Obligations	0	0	0	0	725K	2.62M	84K	832K	577K	985K
Deferred Tax Liabilities	0	0	0	0	0	11.15M	0	1.38M	762K	0
Other Non-Current Liabilities	4.15M	7.39M	4.24M	22.26M	28.79M	13.23M	14.59M	6.4M	16.7M	30.27M
Total Liabilities	14.26M	11M	7.64M	27.63M	58.28M	128.1M	93.31M	98.48M	91.14M	105.21M
Total Debt+	0	0	0	0	2.01M	30.97M	18.19M	30.43M	16.42M	22.94M
Net Debt	-8.05M	-802.33K	-7.01M	-11.04M	-46.08M	-18.68M	-1.17M	7.44M	-3.59M	-8.02M
Debt / Equity	-	-	-	-	0.02x	0.23x	0.41x	0.77x	0.59x	1.21x
Debt / EBITDA	-	-	-	-	-	-	-	-	3.20x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.70x	-
Interest Coverage	-3.95x	-7.94x	-26.29x	-	-	-	-0.75x	-3.44x	-0.33x	-2.11x
Total Equity+	10.09M	4M	13.42M	7.09M	95.02M	137.57M	44.31M	39.36M	27.72M	18.97M
Equity Growth %	-0.35%	-0.6%	2.36%	-0.47%	12.41%	0.45%	-0.68%	-0.11%	-0.3%	-0.32%
Book Value per Share	463368.52	34331.42	4033.78	181.87	413.11	163.77	30.14	11.78	5.00	3.02
Total Shareholders' Equity	10.09M	4M	13.42M	7.09M	95.02M	137.57M	44.31M	39.36M	27.72M	18.97M
Common Stock	374	82	179	1.75K	1K	3K	0	1K	1K	1K
Retained Earnings	-46.56M	-69.07M	-79.26M	-106.39M	-120.01M	-178.3M	-287.08M	-304.13M	-319.97M	-333.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-112K	-246K	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-10.66M	-13.83M	-15.94M	-13.83M	-28.37M	-25.96M	-28.82M	-5.13M	-1.39M	-1.94M
Operating CF Margin %	-4.16%	-4.29%	-4.36%	-1.89%	-1.03%	-0.4%	-0.3%	-0.05%	-0.02%	-0.03%
Operating CF Growth %	-0.61%	-0.3%	-0.15%	0.13%	-1.05%	0.08%	-0.11%	0.82%	0.73%	-0.4%
Net Income	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.29M	-108.78M	-17.05M	-15.84M	-13.56M
Depreciation & Amortization	874.79K	4.36M	2.59M	2.73M	6.25M	9.2M	10.15M	8.81M	6.72M	5.38M
Stock-Based Compensation	902.95K	2.5M	348.51K	1.02M	1.08M	3.57M	5.25M	6.05M	2.37M	576K
Deferred Taxes	13.55M	1.62M	-1.94M	-80.78K	573.53K	0	0	0	0	0
Other Non-Cash Items	403.78K	1.23M	-6.03M	9.84M	-10.04M	17.87M	75.42M	2.86M	10.02M	11.4M
Working Capital Changes	1.79M	-1.04M	-718.81K	-210.2K	-12.61M	1.68M	-10.86M	-5.8M	-4.66M	-5.73M
Change in Receivables	-5.37K	-355.03K	-50.74K	-1.16M	-3.56M	1.54M	6.53M	-7.15M	5.2M	-7.63M
Change in Inventory	-485.26K	195.43K	-26.75K	-101.1K	-6.95M	2.79M	1.3M	-3.61M	-4.82M	382K
Change in Payables	1.62M	493.22K	-109.71K	134.78K	-1.38M	-3.25M	-7.68M	2.38M	-2.08M	287K
Cash from Investing+	-5.3M	-3.53M	-484.29K	-1.06M	-5.66M	-2.78M	-3.25M	-117K	-329K	-2.56M
Capital Expenditures	-2.25M	-111.61K	-74.71K	-59.85K	0	0	0	0	-329K	-228K
CapEx % of Revenue	0.88%	0.03%	0.02%	0.01%	-	-	-	-	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2K	613.31K	-402.2K	-497.11K	-5.84M	-2.3M	-70K	-112K	0	-2.33M
Cash from Financing+	16.66M	10.19M	22.66M	19.08M	71.07M	30.31M	1.53M	8.87M	-1.26M	15.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.23M	845.19K	-2.08M	14.08M	-44.14M	-6.09M	-4.94M	-4.36M	-2.84M	-6.07M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.91M	-13.94M	-16.02M	-13.89M	-28.37M	-25.96M	-28.82M	-5.13M	-1.72M	-5.17M
FCF Margin %	-5.04%	-4.33%	-4.38%	-1.9%	-1.03%	-0.4%	-0.3%	-0.05%	-0.03%	-0.08%
FCF Growth %	-0.95%	-0.08%	-0.15%	0.13%	-1.04%	0.08%	-0.11%	0.82%	0.67%	-2.01%
FCF per Share	-593169.47	-119661.30	-4812.17	-356.44	-123.36	-30.91	-19.61	-1.54	-0.31	-0.82
FCF Conversion (FCF/Net Income)	0.38x	0.61x	1.56x	0.29x	2.08x	0.45x	0.26x	0.30x	0.09x	0.14x
Interest Paid	0	0	0	0	0	1.25M	3.15M	3.81M	4.04M	2.82M
Taxes Paid	0	0	0	0	0	0	0	0	1.61M	1.42M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-219.29%	-319.61%	-116.94%	-459.89%	-26.68%	-50.12%	-119.62%	-40.76%	-47.24%	-58.1%
Return on Invested Capital (ROIC)	-316.25%	-577.37%	-307.51%	-1029.09%	-70.46%	-52.62%	-101.75%	-28.46%	-3.36%	-33.47%
Gross Margin	62.65%	56%	43.97%	69.92%	70.03%	44.49%	52.02%	62.04%	75.26%	69.04%
Net Margin	-1099.73%	-698.67%	-278.36%	-644.33%	-49.29%	-88.81%	-112.53%	-15.88%	-24.31%	-20.43%
Debt / Equity	-	-	-	-	0.02x	0.23x	0.41x	0.77x	0.59x	1.21x
Interest Coverage	-3.95x	-7.94x	-26.29x	-	-	-	-0.75x	-3.44x	-0.33x	-2.11x
FCF Conversion	0.38x	0.61x	1.56x	0.29x	2.08x	0.45x	0.26x	0.30x	0.09x	0.14x
Revenue Growth	878.85%	25.72%	13.61%	100.01%	277.47%	137.52%	47.29%	11.1%	-39.31%	1.84%

Revenue by Segment

	2015	2017	2020	2021	2022	2023	2024
Consumer Health	-	-	-	-	-	33.6M	15.82M
Consumer Health Growth	-	-	-	-	-	-	-52.92%
Consumer Health Portfolio	-	-	-	-	35.55M	-	-
Consumer Health Portfolio Growth	-	-	-	-	-	-	-
Pediatric Portfolio	-	-	-	-	16.08M	-	-
Pediatric Portfolio Growth	-	-	-	-	-	-	-
Aytu Consumer Health	-	-	-	32.95M	-	-	-
Aytu Consumer Health Growth	-	-	-	-	-	-	-
Aytu Bio Pharma	-	-	-	32.68M	-	-	-
Aytu Bio Pharma Growth	-	-	-	-	-	-	-
Product Revenue	-	-	27.63M	-	-	-	-
Product Revenue Growth	-	-	-	-	-	-	-
License Revenue	-	-	-	-	-	-	-
License Revenue Growth	-	-	-	-	-	-	-
AYTU Bioscience, Inc.	-	3.17M	-	-	-	-	-
AYTU Bioscience, Inc. Growth	-	-	-	-	-	-	-
Aytu Women's Health	-	47K	-	-	-	-	-
Aytu Women's Health Growth	-	-	-	-	-	-	-

Revenue by Geography

	2015	2017	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	94.61M	106.92M	80.91M
UNITED STATES Growth	-	-	-	-	-	13.01%	-24.32%
Non-US	-	-	-	-	2.06M	481K	91K
Non-US Growth	-	-	-	-	-	-76.68%	-81.08%
Non Us	-	-	-	4.95M	-	-	-
Non Us Growth	-	-	-	-	-	-	-
KOREA, REPUBLIC OF	500K	-	-	-	-	-	-
KOREA, REPUBLIC OF Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Aytu BioPharma, Inc. (AYTU) reported $63.7M in revenue for fiscal year 2025. This represents a 3639671% increase from $0.0M in 2012.

Aytu BioPharma, Inc. (AYTU) grew revenue by 1.8% over the past year. Growth has been modest.

Aytu BioPharma, Inc. (AYTU) reported a net loss of $13.1M for fiscal year 2025.

Dividend & Returns

Aytu BioPharma, Inc. (AYTU) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.

Aytu BioPharma, Inc. (AYTU) had negative free cash flow of $1.5M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Aytu BioPharma, Inc. (AYTU) 10-Year Financial Performance & Capital Metrics

AYTU • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

Revenue $66M +1.8%
EBITDA -$2M -147.7%
Net Income -$14M +14.4%
EPS (Diluted) -2.16 +24.5%
Gross Margin 69.04% -8.3%
EBITDA Margin -3.69% -146.9%
Operating Margin -11.79% -383.1%
Net Margin -20.43% +15.9%
ROE -58.1% -23.0%
ROIC -33.47% -894.7%
Debt/Equity 1.21 +104.2%
Interest Coverage -2.11 -536.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)
✓Strong 5Y sales CAGR of 19.2%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 13.4% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y73.94%

5Y19.16%

3Y-11.78%

TTM-5.39%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-109.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM-147.99%

ROCE

10Y Avg-70.95%

5Y Avg-35.52%

3Y Avg-13.29%

Latest-13.3%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.49B	135.33	41.13	24.81%	15.95%	14.25%	4.13%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.97B	51.80	39.24	8.94%	-2.8%	-1.82%	5.76%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.94M	7.01	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.02M	2.75	-1.27	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	429.45M	3.52	-6.90	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.50	-42.16	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	17.39B	35.17	-4042.53			-67.02%		0.01

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	2.56M	3.22M	3.66M	7.32M	27.63M	65.63M	96.67M	107.4M	65.18M	66.38M
Revenue Growth %	8.79%	0.26%	0.14%	1%	2.77%	1.38%	0.47%	0.11%	-0.39%	0.02%
Cost of Goods Sold+	957.08K	1.42M	2.05M	2.2M	8.28M	36.43M	46.39M	40.77M	16.13M	20.55M
COGS % of Revenue	0.37%	0.44%	0.56%	0.3%	0.3%	0.56%	0.48%	0.38%	0.25%	0.31%
Gross Profit+	1.61M	1.8M	1.61M	5.12M	19.35M	29.2M	50.28M	66.63M	49.05M	45.83M
Gross Margin %	0.63%	0.56%	0.44%	0.7%	0.7%	0.44%	0.52%	0.62%	0.75%	0.69%
Gross Profit Growth %	8.24%	0.12%	-0.11%	2.18%	2.78%	0.51%	0.72%	0.33%	-0.26%	-0.07%
Operating Expenses+	15.81M	20.66M	19.45M	21.96M	40.48M	88.07M	160.19M	83.7M	50.65M	53.66M
OpEx % of Revenue	6.17%	6.41%	5.32%	3%	1.47%	1.34%	1.66%	0.78%	0.78%	0.81%
Selling, General & Admin	8.83M	17.61M	17.73M	19.24M	31.06M	55.81M	69.88M	70.08M	42.04M	38.28M
SG&A % of Revenue	3.44%	5.47%	4.84%	2.63%	1.12%	0.85%	0.72%	0.65%	0.64%	0.58%
Research & Development	6.32M	1.35M	167.59K	589.07K	1.72M	5.62M	12.66M	4.09M	2.77M	1.33M
R&D % of Revenue	2.47%	0.42%	0.05%	0.08%	0.06%	0.09%	0.13%	0.04%	0.04%	0.02%
Other Operating Expenses	664.71K	1.71M	6.28M	2.14M	7.7M	26.64M	77.65M	9.52M	5.84M	14.05M
Operating Income+	-21.7M	-20.13M	-19.7M	-16.85M	-21.13M	-58.87M	-109.91M	-17.07M	-1.59M	-7.83M
Operating Margin %	-8.47%	-6.25%	-5.38%	-2.3%	-0.76%	-0.9%	-1.14%	-0.16%	-0.02%	-0.12%
Operating Income Growth %	-1.84%	0.07%	0.02%	0.14%	-0.25%	-1.79%	-0.87%	0.84%	0.91%	-3.92%
EBITDA+	-20.83M	-18.28M	-17.85M	-14.61M	-15.42M	-49.67M	-99.76M	-8.25M	5.13M	-2.45M
EBITDA Margin %	-8.13%	-5.67%	-4.88%	-2%	-0.56%	-0.76%	-1.03%	-0.08%	0.08%	-0.04%
EBITDA Growth %	-1.77%	0.12%	0.02%	0.18%	-0.06%	-2.22%	-1.01%	0.92%	1.62%	-1.48%
D&A (Non-Cash Add-back)	874.79K	1.84M	1.85M	2.24M	5.71M	9.2M	10.15M	8.81M	6.72M	5.38M
EBIT	-22.69M	-19.97M	-17.84M	-16.85M	-17.92M	-38.24M	-38.1M	-12.09M	-5.32M	-10.04M
Net Interest Income+	-5.49M	-2.53M	-749.42K	0	0	0	-147.48M	-4.96M	-4.79M	-3.7M
Interest Income	0	0	0	0	0	0	14K	0	0	0
Interest Expense	5.49M	2.53M	749.42K	0	0	0	147.5M	4.96M	4.79M	3.7M
Other Income/Expense	-6.48M	-2.38M	9.51M	-10.29M	7.51M	840K	1.02M	14K	-8.79M	-5.92M
Pretax Income+	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.03M	-108.89M	-17.05M	-10.38M	-13.74M
Pretax Margin %	-11%	-6.99%	-2.78%	-3.71%	-0.49%	-0.88%	-1.13%	-0.16%	-0.16%	-0.21%
Income Tax+	0	0	0	20.04M	0	259K	-110K	0	2.14M	437K
Effective Tax Rate %	1%	1%	1%	1.74%	1%	1%	1%	1%	1.53%	0.99%
Net Income+	-28.18M	-22.51M	-10.19M	-47.17M	-13.62M	-58.29M	-108.78M	-17.05M	-15.84M	-13.56M
Net Margin %	-11%	-6.99%	-2.78%	-6.44%	-0.49%	-0.89%	-1.13%	-0.16%	-0.24%	-0.2%
Net Income Growth %	-2.65%	0.2%	0.55%	-3.63%	0.71%	-3.28%	-0.87%	0.84%	0.07%	0.14%
Net Income (Continuing)	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.29M	-108.78M	-17.05M	-12.52M	-14.18M
Discontinued Operations	0	0	0	0	0	0	0	0	-3.32M	620K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-193194.38	-3061.23	-1210.28	-60.20	-69.60	-74.01	-5.11	-2.86	-2.16
EPS Growth %	-1.35%	0.85%	0.98%	0.6%	0.95%	-0.16%	-0.06%	0.93%	0.44%	0.24%
EPS (Basic)	-999999.00	-193194.38	-3061.23	-1210.28	-60.20	-69.60	-74.01	-5.11	-2.86	-2.16
Diluted Shares Outstanding	22	117	3.33K	38.97K	230K	840K	1.47M	3.34M	5.54M	6.28M
Basic Shares Outstanding	22	117	3.33K	38.97K	230K	840K	1.47M	3.34M	5.54M	6.28M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	10.12M	3.03M	9.47M	15.43M	75.42M	105.23M	59.93M	72.83M	61.89M	79.18M
Cash & Short-Term Investments	9.1M	802.33K	7.01M	11.04M	48.08M	49.65M	19.36M	22.98M	20.01M	30.95M
Cash Only	8.05M	802.33K	7.01M	11.04M	48.08M	49.65M	19.36M	22.98M	20.01M	30.95M
Short-Term Investments	1.04M	0	0	0	0	0	0	0	0	0
Accounts Receivable	162.43K	528.04K	578.78K	1.74M	5.63M	28.18M	21.71M	28.94M	23.53M	31.16M
Days Sales Outstanding	23.14	59.83	57.72	86.8	74.41	156.7	81.98	98.34	131.74	171.31
Inventory	524.71K	1.31M	1.34M	1.44M	10M	16.34M	10.85M	11.99M	12.14M	11.43M
Days Inventory Outstanding	200.11	337.93	238.34	238.7	440.72	163.69	85.37	107.4	274.75	203.08
Other Current Assets	121.98K	75.21K	100K	250K	5.99M	1.29M	633K	868K	1.12M	0
Total Non-Current Assets+	14.22M	11.97M	11.59M	19.29M	77.87M	160.43M	77.69M	65.01M	56.97M	45M
Property, Plant & Equipment	231.43K	647.25K	219K	203.73K	893K	8.7M	6.3M	3.87M	1.52M	1.59M
Fixed Asset Turnover	11.07x	4.98x	16.71x	35.93x	30.94x	7.54x	15.35x	27.76x	42.83x	41.67x
Goodwill	221K	238.43K	0	0	28.09M	65.8M	0	0	0	0
Intangible Assets	13.55M	11.08M	11.37M	19.08M	48.85M	85.46M	70.63M	58.97M	52.45M	42.2M
Long-Term Investments	0	0	0	0	0	-10.91M	0	0	0	0
Other Non-Current Assets	216.36K	2.89K	4.72K	2.2K	33K	465K	766K	792K	2.23M	1.2M
Total Assets+	24.34M	15M	21.06M	34.72M	153.29M	265.67M	137.62M	137.84M	118.86M	124.18M
Asset Turnover	0.11x	0.21x	0.17x	0.21x	0.18x	0.25x	0.70x	0.78x	0.55x	0.53x
Asset Growth %	0.34%	-0.38%	0.4%	0.65%	3.41%	0.73%	-0.48%	0%	-0.14%	0.04%
Total Current Liabilities+	10.1M	3.61M	3.39M	5.37M	28.76M	109.44M	64.44M	69.02M	62.23M	63.06M
Accounts Payable	2.32M	2.22M	2.12M	2.13M	11.64M	19.25M	10.99M	13.48M	10.31M	10.6M
Days Payables Outstanding	885.77	571.8	377.3	353.64	513.05	192.91	86.45	120.67	233.41	188.28
Short-Term Debt	0	0	0	0	982K	24.6M	3.81M	8.74M	4.96M	10.92M
Deferred Revenue (Current)	0	0	0	0	339.34K	1000K	0	0	0	0
Other Current Liabilities	6.58M	1.05M	734.43K	2.23M	8M	1.47M	23.84M	41.12M	42.35M	26.14M
Current Ratio	1.00x	0.84x	2.79x	2.87x	2.62x	0.96x	0.93x	1.06x	0.99x	1.26x
Quick Ratio	0.95x	0.48x	2.40x	2.60x	2.27x	0.81x	0.76x	0.88x	0.80x	1.07x
Cash Conversion Cycle	-662.53	-174.05	-81.25	-28.15	2.08	127.48	80.89	85.07	173.08	186.1
Total Non-Current Liabilities+	4.15M	7.39M	4.24M	22.26M	29.52M	18.66M	28.87M	29.47M	28.91M	42.15M
Long-Term Debt	0	0	0	0	0	2.8M	14.2M	20.86M	10.88M	10.89M
Capital Lease Obligations	0	0	0	0	725K	2.62M	84K	832K	577K	985K
Deferred Tax Liabilities	0	0	0	0	0	11.15M	0	1.38M	762K	0
Other Non-Current Liabilities	4.15M	7.39M	4.24M	22.26M	28.79M	13.23M	14.59M	6.4M	16.7M	30.27M
Total Liabilities	14.26M	11M	7.64M	27.63M	58.28M	128.1M	93.31M	98.48M	91.14M	105.21M
Total Debt+	0	0	0	0	2.01M	30.97M	18.19M	30.43M	16.42M	22.94M
Net Debt	-8.05M	-802.33K	-7.01M	-11.04M	-46.08M	-18.68M	-1.17M	7.44M	-3.59M	-8.02M
Debt / Equity	-	-	-	-	0.02x	0.23x	0.41x	0.77x	0.59x	1.21x
Debt / EBITDA	-	-	-	-	-	-	-	-	3.20x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.70x	-
Interest Coverage	-3.95x	-7.94x	-26.29x	-	-	-	-0.75x	-3.44x	-0.33x	-2.11x
Total Equity+	10.09M	4M	13.42M	7.09M	95.02M	137.57M	44.31M	39.36M	27.72M	18.97M
Equity Growth %	-0.35%	-0.6%	2.36%	-0.47%	12.41%	0.45%	-0.68%	-0.11%	-0.3%	-0.32%
Book Value per Share	463368.52	34331.42	4033.78	181.87	413.11	163.77	30.14	11.78	5.00	3.02
Total Shareholders' Equity	10.09M	4M	13.42M	7.09M	95.02M	137.57M	44.31M	39.36M	27.72M	18.97M
Common Stock	374	82	179	1.75K	1K	3K	0	1K	1K	1K
Retained Earnings	-46.56M	-69.07M	-79.26M	-106.39M	-120.01M	-178.3M	-287.08M	-304.13M	-319.97M	-333.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-112K	-246K	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-10.66M	-13.83M	-15.94M	-13.83M	-28.37M	-25.96M	-28.82M	-5.13M	-1.39M	-1.94M
Operating CF Margin %	-4.16%	-4.29%	-4.36%	-1.89%	-1.03%	-0.4%	-0.3%	-0.05%	-0.02%	-0.03%
Operating CF Growth %	-0.61%	-0.3%	-0.15%	0.13%	-1.05%	0.08%	-0.11%	0.82%	0.73%	-0.4%
Net Income	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.29M	-108.78M	-17.05M	-15.84M	-13.56M
Depreciation & Amortization	874.79K	4.36M	2.59M	2.73M	6.25M	9.2M	10.15M	8.81M	6.72M	5.38M
Stock-Based Compensation	902.95K	2.5M	348.51K	1.02M	1.08M	3.57M	5.25M	6.05M	2.37M	576K
Deferred Taxes	13.55M	1.62M	-1.94M	-80.78K	573.53K	0	0	0	0	0
Other Non-Cash Items	403.78K	1.23M	-6.03M	9.84M	-10.04M	17.87M	75.42M	2.86M	10.02M	11.4M
Working Capital Changes	1.79M	-1.04M	-718.81K	-210.2K	-12.61M	1.68M	-10.86M	-5.8M	-4.66M	-5.73M
Change in Receivables	-5.37K	-355.03K	-50.74K	-1.16M	-3.56M	1.54M	6.53M	-7.15M	5.2M	-7.63M
Change in Inventory	-485.26K	195.43K	-26.75K	-101.1K	-6.95M	2.79M	1.3M	-3.61M	-4.82M	382K
Change in Payables	1.62M	493.22K	-109.71K	134.78K	-1.38M	-3.25M	-7.68M	2.38M	-2.08M	287K
Cash from Investing+	-5.3M	-3.53M	-484.29K	-1.06M	-5.66M	-2.78M	-3.25M	-117K	-329K	-2.56M
Capital Expenditures	-2.25M	-111.61K	-74.71K	-59.85K	0	0	0	0	-329K	-228K
CapEx % of Revenue	0.88%	0.03%	0.02%	0.01%	-	-	-	-	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2K	613.31K	-402.2K	-497.11K	-5.84M	-2.3M	-70K	-112K	0	-2.33M
Cash from Financing+	16.66M	10.19M	22.66M	19.08M	71.07M	30.31M	1.53M	8.87M	-1.26M	15.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.23M	845.19K	-2.08M	14.08M	-44.14M	-6.09M	-4.94M	-4.36M	-2.84M	-6.07M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.91M	-13.94M	-16.02M	-13.89M	-28.37M	-25.96M	-28.82M	-5.13M	-1.72M	-5.17M
FCF Margin %	-5.04%	-4.33%	-4.38%	-1.9%	-1.03%	-0.4%	-0.3%	-0.05%	-0.03%	-0.08%
FCF Growth %	-0.95%	-0.08%	-0.15%	0.13%	-1.04%	0.08%	-0.11%	0.82%	0.67%	-2.01%
FCF per Share	-593169.47	-119661.30	-4812.17	-356.44	-123.36	-30.91	-19.61	-1.54	-0.31	-0.82
FCF Conversion (FCF/Net Income)	0.38x	0.61x	1.56x	0.29x	2.08x	0.45x	0.26x	0.30x	0.09x	0.14x
Interest Paid	0	0	0	0	0	1.25M	3.15M	3.81M	4.04M	2.82M
Taxes Paid	0	0	0	0	0	0	0	0	1.61M	1.42M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-219.29%	-319.61%	-116.94%	-459.89%	-26.68%	-50.12%	-119.62%	-40.76%	-47.24%	-58.1%
Return on Invested Capital (ROIC)	-316.25%	-577.37%	-307.51%	-1029.09%	-70.46%	-52.62%	-101.75%	-28.46%	-3.36%	-33.47%
Gross Margin	62.65%	56%	43.97%	69.92%	70.03%	44.49%	52.02%	62.04%	75.26%	69.04%
Net Margin	-1099.73%	-698.67%	-278.36%	-644.33%	-49.29%	-88.81%	-112.53%	-15.88%	-24.31%	-20.43%
Debt / Equity	-	-	-	-	0.02x	0.23x	0.41x	0.77x	0.59x	1.21x
Interest Coverage	-3.95x	-7.94x	-26.29x	-	-	-	-0.75x	-3.44x	-0.33x	-2.11x
FCF Conversion	0.38x	0.61x	1.56x	0.29x	2.08x	0.45x	0.26x	0.30x	0.09x	0.14x
Revenue Growth	878.85%	25.72%	13.61%	100.01%	277.47%	137.52%	47.29%	11.1%	-39.31%	1.84%

Revenue by Segment

	2015	2017	2020	2021	2022	2023	2024
Consumer Health	-	-	-	-	-	33.6M	15.82M
Consumer Health Growth	-	-	-	-	-	-	-52.92%
Consumer Health Portfolio	-	-	-	-	35.55M	-	-
Consumer Health Portfolio Growth	-	-	-	-	-	-	-
Pediatric Portfolio	-	-	-	-	16.08M	-	-
Pediatric Portfolio Growth	-	-	-	-	-	-	-
Aytu Consumer Health	-	-	-	32.95M	-	-	-
Aytu Consumer Health Growth	-	-	-	-	-	-	-
Aytu Bio Pharma	-	-	-	32.68M	-	-	-
Aytu Bio Pharma Growth	-	-	-	-	-	-	-
Product Revenue	-	-	27.63M	-	-	-	-
Product Revenue Growth	-	-	-	-	-	-	-
License Revenue	-	-	-	-	-	-	-
License Revenue Growth	-	-	-	-	-	-	-
AYTU Bioscience, Inc.	-	3.17M	-	-	-	-	-
AYTU Bioscience, Inc. Growth	-	-	-	-	-	-	-
Aytu Women's Health	-	47K	-	-	-	-	-
Aytu Women's Health Growth	-	-	-	-	-	-	-

Revenue by Geography

	2015	2017	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	94.61M	106.92M	80.91M
UNITED STATES Growth	-	-	-	-	-	13.01%	-24.32%
Non-US	-	-	-	-	2.06M	481K	91K
Non-US Growth	-	-	-	-	-	-76.68%	-81.08%
Non Us	-	-	-	4.95M	-	-	-
Non Us Growth	-	-	-	-	-	-	-
KOREA, REPUBLIC OF	500K	-	-	-	-	-	-
KOREA, REPUBLIC OF Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Aytu BioPharma, Inc. (AYTU) reported $63.7M in revenue for fiscal year 2025. This represents a 3639671% increase from $0.0M in 2012.

Aytu BioPharma, Inc. (AYTU) grew revenue by 1.8% over the past year. Growth has been modest.

Aytu BioPharma, Inc. (AYTU) reported a net loss of $13.1M for fiscal year 2025.

Dividend & Returns

Aytu BioPharma, Inc. (AYTU) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.

Aytu BioPharma, Inc. (AYTU) had negative free cash flow of $1.5M in fiscal year 2025, likely due to heavy capital investments.